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ABSTRACT
The graft-versus-leukemia effect of allogeneic blood or marrow transplantation is a dramatic example of the
power of the immune system to eradicate malignant disease. In this personal essay, adapted from the inaugural
Mortimer M. Bortin Lecture presented at the 2004 Tandem BMT Meetings, the author recounts early efforts
by Bortin and others to manipulate the graft-versus-leukemia effect and separate it from the potentially fatal
complications of graft-versus-host disease.
© 2004 American Society for Blood and Marrow Transplantation
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gNTRODUCTION
It is an honor to give the Mortimer M. Bortin
ecture at the 2004 Tandem BMTMeetings. Because
t is the inaugural Bortin Lecture, I have chosen to
ecount the history of the search for separation of
raft-versus-leukemia (GVL) and graft-versus-host
GVH) reactions as a tribute to Dr. Bortin, who was a
ioneer in the use of animal models for such studies
nd was a cofounder and scientiﬁc director of the
nternational Bone Marrow Transplant Registry (IB-
TR). For the most part, I will focus on work per-
ormed in animal models by him and his colleagues
nd parallel them with developments in the clinical
rena. This is not intended to be a state-of-the-ﬁeld or
n all-encompassing review. It is the recounting of a
ourney that for me personally has spanned the last 3
ecades. My aim is to impart to newcomers and “not-
o-new” comers to the ﬁeld of GVL research some of
he history behind what is one of the most dramatic
xamples of the power of the immune system to de-
troy malignancy.
A casual survey of the literature reveals the degree
o which studies on GVL reactivity have evolved.
efore 1970, no articles used the phrase graft-versus- a
B&MTeukemia. Over the next decade, 12 articles dealing
ith animal models used the phrase. Nine were from
ortin and colleagues. Only a single article, by Wei-
en et al. in 1979 [1], used the term in reference to
ork in humans. It was not until the 1980s that the
oncept of GVL reactivity gained broad acceptance in
he clinical world. Now clinical reports dealing with
he induction or manipulation of GVL/GVH reac-
ions outnumber those using animal models, and due
onsideration is given in the design of virtually every
linical protocol to potential effects on GVL reactiv-
ty, so as not to compromise it. The GVL effect of
lood and marrow transplantation (BMT) has become
he most successful form of adoptive cellular immu-
otherapy, and, as noted by Richard Champlin earlier
n this meeting, BMT has evolved into an effective
latform for delivery of cellular immune therapies and
ot simply for delivery of high-dose chemotherapy.
N THE BEGINNING: RADIATION SICKNESS AND
ECONDARY DISEASE
Much of the impetus for work in the ﬁeld of BMT
rew out of fears generated with the dropping of
tomic bombs on Hiroshima and Nagasaki in 1945
505
a
w
i
c
f
U
r
s
v
a
w
r
t
L
H
i
L
1
p
s
i
n
t
[
s
o
e
L
r
p
t
f
s
m
b
d
e
h
t
A
t
B
e
e
o
H
H
g
c
i
m
m
w
l
o
m
w
r
i
a
a
p
w
h
c
m
b
I
w
h
h
u
w
l
r
l
t
m
c
r
e
m
t
c
t
s
i
t
r
s
m
m
I
h
h
B
M
w
i
n
s
s
t
s
c
R. L. Truitt
5nd the subsequent paranoia that became the “cold
ar.” Radiation sickness was a new and very real threat
n the nascent nuclear age. A cure was needed for what
ame to be called the bone marrow syndrome resulting
rom excessive radiation exposure. The military in the
nited States actively supported research into a cure for
adiation sickness. The Ofﬁce of Naval Research spon-
ored Bortin’s early work on fetal liver [2,3] as a “uni-
ersal” source of donor cells that might be used to treat
ccidental or tactical exposure to nuclear radiation.
Although many helped to establish the ground-
ork, the ﬁrst successful experiments showing that
adiation sickness could be cured in mice by transplan-
ation of normal marrow are widely credited to Egon
orenz, who was working at the National Institutes of
ealth in Bethesda, MD. For years, Bortin had hang-
ng in his ofﬁce a framed copy of the letter from
orenz to his assistant Delta Uphoff, dated August 6,
950. In it Lorenz wrote, “After talking with many
eople, I [am] beginning to be convinced that we
hould not only try transfusions in mice at different
ntervals after irradiation but also injection (intrave-
ous) of a normal bone marrow suspension at different
imes after irradiation with the idea of repopulation
of] the destroyed bone marrow. As to technique, it
hould not be too difﬁcult to get some bone marrow
ut as only little may be necessary to produce the
ffect.” Lorenz was on vacation at the Old England
ake Hotel in Windermere, England. By the time he
eturned to Bethesda, Uphoff had completed the ex-
eriments. The results were published in the Journal of
he National Cancer Institute 1 year later [4,5].
Soon thereafter, workers in the ﬁeld were con-
ronted with a formidable new syndrome that con-
isted of wasting, diarrhea, skin lesions, and death in
ice that were injected with homologous (allogeneic)
one marrow (BM). It was called secondary disease to
istinguish it from the primary sickness of radiation
xposure, but it was referred to as wasting disease,
omologous disease, and runting syndrome in other set-
ings, some of which did not involve irradiation.
mong the earliest investigators to deﬁne and attempt
o unravel the pathophysiology of this syndrome were
arnes et al. [6], van Bekkum and Vos [7], van Bekkum
t al. [8,9], Trentin [10], and Thompson et al. [11].
At the same time, attempts were under way to
xploit radiation in the treatment of leukemia and
ther cancers. The ﬁrst published report was from
ollcroft et al. [12] at the National Institutes of
ealth, who used a transplantable lymphosarcoma in
uinea pigs. They found that local irradiation of sub-
utaneous tumors was ineffective but that whole-body
rradiation at much lower doses worked well. The
aximum tolerated whole-body dose was approxi-
ately 1000 R because of intestinal radiation death,
hich was not prevented by BM transplantation. The
ength of remission correlated linearly with the dose o
06f radiation, but they obtained no permanent leuke-
ia cures by using radiation alone. Much of the early
ork in radiation biology was focused on the inherent
adiation resistance of leukemia and how to overcome
t [13,14].
In 1956 and 1957, Barnes et al. [15] and Barnes
nd Loutit [16] reported the ﬁrst successes with BMT
s a treatment for leukemia. Elimination of a trans-
lantable leukemia (“151/1”) was obtained after
hole-body irradiation and infusion of homologous or
eterologous (xenogeneic; rat) BM and lymphoid
ells, but not isologous (syngeneic) cells, into CBA
ice, as conﬁrmed by adoptive transfer of spleens (a
ioassay) from moribund animals to healthy hosts.
rradiation alone did not eliminate the leukemia; this
as attributed to an immunologic reaction against the
ost—with the tumor being considered part of the
ost. In their seminal article, Barnes et al. [15] artic-
lated for the ﬁrst time the promise and the problem
ith manipulating the immune system to eliminate
eukemia in the context of BMT: “. . .if the dose of x
ays sufﬁcient to kill the animal is not 100% lethal to
eukaemic cells, the malignant condition would in
hese circumstances recur [following syngeneic bone
arrow transplantation] by growth from the surviving
ells, since neither host nor graft has the ability to
esist; but, if homologous bone marrow from a differ-
nt strain of mouse were given, the colonizing cells
ight retain the capacity of the donor to destroy by
he reaction of immunity these residual leukaemic
ells—and perhaps also the host.” They concluded, “If
he experiences of several laboratories could be pooled
ome general laws might be evolved which should help
n planning an extrapolation from mouse to man for
reatment of those types of leukaemia which are so
apidly fatal as to warrant the use of desperate mea-
ures.” At the time, secondary disease was believed by
any to invalidate this mode of treatment for leuke-
ia. The race to separate GVL from GVH was on.
S GVL SEPARABLE FROM GVH?
Several groups embraced the idea of using a foreign
ematopoietic transplant to immunologically attack the
ost and, by extension, the tumor. Barnes et al. [15],
arnes and Loutit [16], De Vries and Vos [17], and
athe´ and Bernard [18] were among the early pioneers
ho achieved permanent cures in small numbers of an-
mals. The studies of Mathe´ and Bernard are particularly
otable because they were among the earliest to use a
pontaneously arising leukemia/lymphoma, ie, the Ak
train. Previously, most studies had been performed with
ransplantable tumors. Jacob Furth derived the AKR
train between 1928 and 1936 [19]. Furth sought to
reate a high-leukemia-incidence strain by mating pairs
f strain A mice that he was told had a predisposition to
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Bevelop leukemia. Of the mating pairs (Aa, Ab, Ac, and
o on), the Ak pair yielded progeny with the highest
ncidence of leukemia. The R was added to the strain’s
ame when the colony was moved to Rockefeller Uni-
ersity. Bortin and colleagues made extensive use of the
KR strain in the quest for separation of GVL and
VH reactions.
In a classic monograph, Radiation Chimeras, pub-
ished in 1967 [20], van Bekkum and de Vries reviewed
arly attempts to control what was referred to as the
raft-versus-tumor (GVT) reaction, as well as early clin-
cal work. Almost all failed. They wrote, “It seems to be
xtremely difﬁcult to induce that precise degree of graft
ersus host reactivity which will kill the leukaemic cells
ut which is at the same time mild enough to allow
urvival of the host.” The use of the term graft versus
umor instead of graft versus leukemia is noteworthy. Per-
aps it is an example of going “back to the future” given
he current interest in extending the antitumor effect
eyond hematologic malignancies [21].
In addition to the work of Mathe´, Trentin, and
thers, van Bekkum and de Vries cited early work
rom the Cooperstown group who reported “a tem-
orary and incomplete take of homologous bone mar-
ow in a heavily irradiated leukaemic patient” who had
no clear-cut symptoms of secondary disease. . .at au-
opsy” [20]. The Cooperstown group [22] was led by
uture Nobel Laureate E. Donnal Thomas. He and his
eam would perfect many of the techniques for BMT
y using canine models, including dogs with malig-
ancies [23-25], ultimately leading to the successful
ranslation of BMT to clinical practice [26].
Among the early pioneers in the ﬁeld of GVL/
VH who had a strong inﬂuence on Bortin’s research
as Milivoj Boranic´ of the Boskovic Institute in
agreb, Yugoslavia. Boranic´ and a number of Yugo-
lavian colleagues explored the temporal aspects of
VH and GVL reactions. In the 1970s, Silobrcˇic´ et al.
27] and Vitale et al. [28] deﬁned 3 temporal phases of
VH reactivity: (1) homing and recognition, (2) acti-
ation and proliferation, and (3) emigration into and
njury of target tissues. Boranic´ [29] had previously
dentiﬁed lymphohematopoietic tissues as the ﬁrst tar-
et of the GVH reaction. He believed that the per-
anent presence of the potentially lethal donor graft
as not needed and that it could be replaced by a less
ggressive one after leukemia cells had perished, a
rocedure he called rescuing the host [29-32]. At-
empts to induce transient GVH reactivity were later
ade in dogs [33,34] and monkeys [35].
In the mid 1960s, a viral etiology of leukemia was
uspected, in part because of the isolation of a leuke-
ogenic virus from AKR mice by Ludwik Gross
36,37]. Alex Fefer, Jim McCoy, and John Glynn were
ctively investigating the induction of immunity to
umors induced by murine leukemia viruses (MuLV)
38-40]. This work laid the foundation for subsequent b
B&MTuccesses in improving the antitumor speciﬁcity of
ellular therapies. Fefer, along with his later col-
eagues in Seattle—Martin Cheever and Phil Green-
erg—pursued the development of adoptive chemo-
mmunotherapy for the treatment of leukemia [41-
3]. This work paralleled that in the GVL/GVH
rena and provided a wealth of sound experimental
ata that were highly instructive for imparting leuke-
ia speciﬁcity to animal models of BMT. The current
ork of Greenberg, Stan Riddell, Edus Warren, and
o-workers with cloned T cells and GVL reactivity
gainst minor histocompatibility antigens (miHA)
44-47] is a legacy of the Fefer laboratory.
Billingham [48] ﬁrst elaborated the requirements
or induction of GVH reactivity in 1966. During the
ubsequent decade, Klein and Chiang [49] docu-
ented the importance of the K, I, and D regions of
he H-2 complex in inducing graft-versus-host disease
GVHD). Later, Korngold and Sprent [50] showed
hat T cells were essential for GVHD directed against
iHA. These and other studies of GVH reactivity and
isease contributed much to the burgeoning ﬁeld of
ransplant immunology—too much by too many peo-
le to cover here. Out of editorial necessity, I have
imited this essay primarily to studies that relate to the
VL effect. In doing so, I have certainly failed to cite
any seminal studies that contributed to unraveling
he GVH syndrome itself, as well as the vast literature
n T-cell biology that coevolved with such studies.
At the start of the 1970s, a central issue was whether
GVL effect existed and, if so, whether it could be
eparated fromGVH reactivity (Figure 1A). The answer
ould dictate how to approach the manipulation of im-
une reactions—at least in an era when monoclonal
ntibodies were unknown, when Herzenberg had only
ecently invented ﬂow cytometry, when T-cell growth
actor and T-cell cloning were a decade away, and when
he precise mechanism by which major histocompatibil-
ty complex (MHC) molecules controlled immune re-
ponses was just beginning to be worked out.
Bortin believed strongly that there should be a
ystem to quantify the leukemia-killing capacity of
onor cells for comparison.1 He and his colleagues
escribed a theoretical cytokinetic construct for use in
The need to quantify GVL reactivity is just as important today.
oo many articles make cavalier and often inappropriate use of
erms such as preserving and sparing GVL reactivity without data to
ubstantiate that no change in the potency of GVL reactivity has
ccurred. For example, if a GVL reaction is reduced by 99.9% as a
esult of some experimental manipulation designed to prevent
VHD, one cannot state that GVL has been preserved or spared,
ven if it is sufﬁcient to eliminate a lethal challenge of leukemia.
itration of the leukemia or effector cell doses should be used to
ocument the robustness of GVL reactivity and assess whether an
xperimental manipulation alters it. Retention of GVL reactivity may
e a more appropriate phrase if quantitation is not performed.
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5omparing the GVL effect of cells from different
onors in an article published in Science in 1973 [51].
ater that year, Bortin, together with Al Rimm and
igure 1. Evolution of models used by the author to describe the
elationship between GVL and GVH reactivity over the past 3
ecades. A, Model circa 1975 (R. Truitt, unpublished data). At issue
as whether the GVL effect of allogeneic BMT was separable from
VHD. If distinct (or overlapping) cell populations were respon-
ible, then it might be possible to have a GVL reaction without
VHD. B, Model circa 1985 [88]—the clonal basis for GVL and
VH reactivity was established. Distinct effector cells capable of
eukemia-speciﬁc killing were identiﬁed, including NK/LAK cells
“C”) and antigen-speciﬁc T cells (“D”). Some allospeciﬁc CTL
lones caused GVHD (“A”), but others did not (“B”). The impor-
ance of cytokines in the activation and clonal expansion of GVL-
peciﬁc effector cells was established (arrow). C, Model circa 1995
287]—the relative contributions of CD4 and CD8 T cells to
VHD were now well established. Cytokines were important for
ctivation and clonal ampliﬁcation of GVL effector cell populations
arrows), but they were also implicated in the pathophysiology of
cute and chronic GVHD. The dichotomy of CD4 T-helper (Th)
ell function was identiﬁed along with the principle of reciprocal
ross-regulation by Th1 and Th2 cytokines (expanded boxes). Some
llospeciﬁc CD8 cytotoxic T-cell clones (Tc) caused lethal
VHD, whereas others did not. Secretion of cytokines (tumor
ecrosis factor [TNF] and interleukin-2 [IL-2]) was thought to
ccount for the strong GVH reactivity of some Tc clones because
ytic activity did not correlate with GVHD. Leukemia-speciﬁc T-
ell clones were identiﬁed, including MHC-restricted and non–
HC-restricted CTLs. The latter seemed to be leukemia speciﬁc
ecause they recognized allogeneic MHC class Ib molecules present
n leukemia but with limited tissue distribution on normal tissues
ie, Qa-1–speciﬁc CTLs).d Saltzstein, published a seminal paper suggesting p
08hat a GVL effect was possible without GVHD [52].
sing a bioassay developed by Lin and Bruce [53] to
uantify leukemia cell kill in vivo, a GVH mortality
ssay, and an in vitro mixed lymphocyte reaction assay,
hey systematically assessed the GVL and GVH reac-
ivity of various donor strains. They found what
eemed to be a disparity between the 2 reactions—ie,
VL reactivity did not always directly correlate with
everity of GVHD, suggesting that the 2 reactions
ight be separable. The biological basis for such a
eparation was not clear at the time.
I ﬁrst met Mortimer Bortin in 1973, while attend-
ng a meeting of the International Society for Exper-
mental Hematology. He chaired the session where I
as presenting my postdoctoral work from the Uni-
ersity of Notre Dame on BMT in germ-free AKR
ice [54,55]. I was anxious to meet him because I was
nterested in moving to Milwaukee, which was close to
y wife’s family. As it turned out, he wanted to meet
e just as much because I had used DBA/2 mice as
onors for AKR hosts in one of my studies [54] and
ad failed to cite his article [52] showing that DBA/2
as the most appropriate donor for use with AKR.We
uickly resolved our differences, and I moved to Mil-
aukee the next year to join his research team in the
ay and Sigmund Winter Research Laboratory,
hich he had established at Mount Sinai Medical
enter.
HE AKR MODEL OF ACUTE LYMPHOBLASTIC
EUKEMIA/LYMPHOMA AND EARLY WORK IN THE
ORTIN LABORATORY
It was important to Bortin that animal models
losely simulate human disease. Inﬂuenced by George
athe´, he adopted the AKR mouse model [56], in
hich acute T-cell lymphoblastic leukemia/lym-
homa develops spontaneously as the result of random
ecombination between endogenous ecotropic and xe-
otropic retroviruses [57,58]. This model was widely
sed for testing chemotherapeutic agents [59,60] and
or elucidating the role of retroviruses in the etiology
f leukemia [36,37]. The tumor begins as a thymic
ymphoma, with subsequent spillover into peripheral
ymphoid and nonlymphoid tissues as the disease
rogresses. The enlarged thymus eventually forces the
ice into a characteristic hunched posture (kyphosis)
s they struggle to breathe.
Bortin learned about irradiation of animals from
ugene Cronkite, a leading radiation biologist of the
ra who was then at the Oak Ridge National Labora-
ory in Tennessee. He visited the Southern Research
nstitute in Birmingham, AL, to learn from Howard
kipper and Frank Shabel Jr how to diagnose early-
tage leukemia in AKR mice. This was done by pal-
ation of the spleen and inguinal lymph nodes (LNs).
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Be bought retired breeders from The Jackson Labo-
atory and maintained a colony of approximately 1000
KR mice that were palpated every Monday. Approx-
mately 50% of AKR mice develop spontaneous leu-
emia by 8 months of age [56]. From this colony, we
ot approximately 30 mice each week that were suit-
ble for use in experiments. The AKR leukemia/lym-
homa model was challenging. In a recent review,
arrett et al. [61] noted 2 key factors that adversely
ffect the GVL reaction: a high proliferation rate for
he disease and an immune-resistant phenotype of
eukemia. Spontaneously arising acute T-cell lympho-
lastic leukemia/lymphoma in AKR mice had both of
hese daunting characteristics.
In early attempts to manipulate GVH reactivity to
btain a GVL effect, we used the concept of a tran-
ient GVH reaction, as ﬁrst proposed by Boranic´
30,32] and Boranic´ and Tonkovic´ [31]; ie, we tried to
ake advantage of the temporal difference in GVL and
VH reactivity and “rescue” the mice after the leu-
emia had been eradicated and before lethal GVHD
eveloped [62]. The ﬁrst step in this 3-step model was
ytoreduction of the spontaneous leukemia/lym-
homa and conditioning of the host with chemoradio-
herapy. We relied heavily on the work of Schabel et
l. [60] for design of the chemotherapy protocol, be-
ause they used the AKR model in their drug-testing
rogram. Step 2 in the model was transplantation of
M and LN cells from the mismatched donor. Bortin
t al. [52,63] had determined earlier that cells from
HC-matched strains (H-2k) had little or no GVL
eactivity but that cells from the MHC-mismatched
BA/2 strain (H-2d) provided a potent antileukemia
ffect with only moderate GVHD. In step 3, mild
onditioning was used to terminate reactivity of the
ismatched donor cells, followed by rescue of the
ost with BM and LN cells from an MHC-matched
train that had minimal GVH reactivity against AKR.
F mice were chosen because of their close immuno-
enetic relationship to AKR—so close, in fact, that
KR leukemia will grow in RF mice. In comparison to
he use of chemoradiotherapy alone or autologous
MT, this protocol resulted in a statistically signiﬁ-
ant prolongation of survival, but ultimately many of
he mice relapsed or died from other complications.
iven the state of clinical BMT (at least in the mid
970s), we decided that if a single transplantation was
arely acceptable to many physicians, convincing
hem that 2 were needed would be next to impossible.
VL IN THE CLINIC—THE EARLY YEARS
Almost immediately after BMT was tested as a
reatment for leukemia in animal models, it was ap-
lied to patients through the work of pioneers such as
eorge Mathe´, E. Donnal Thomas, George Santos, e
B&MTnd, later, Robert Good, John Kersey, and many oth-
rs. Bortin entered the ﬁeld of BMT in the late 1960s,
oving from his earlier work in nephrology. Working
ith Fritz Bach, he processed the marrow used for the
ransplantation of David Zeisett, a 2-year-old boy
ith Wiskott-Aldrich syndrome, who was one of the
rst successful BMT patients in whom donor engraft-
ent was well documented and for whom the mixed
ymphocyte reaction was used to identify a matched
onor [64]. That transplantation was reported in the
ancet in 1968, back to back with a report of another
oy named David, who underwent transplantation for
ongenital immune deﬁciency by the late Robert
ood and colleagues [65]. These were among the
arliest successful marrow transplant patients [66].
In 1970, Bortin wrote “A Compendium of Re-
orted Human Bone Marrow Transplants,” in which
e reviewed some 200 transplantations that had been
eported in the literature up to that time [67]. This
eport brought him a degree of notoriety and led to a
equest from the National College of Surgeons that he
stablish a registry to track the emerging ﬁeld of
linical BMT. Shortly thereafter, the IBMTR was
rganized with Bortin as the scientiﬁc director.
BMT for leukemia matured as a therapy during
he 1970s. Some clinicians viewed it as a passive re-
lacement therapy that simply allowed for the use of
otentially curative high-dose chemoradiotherapy.
rogress was slow, but the group headed by Thomas
68] reported early success in a patient with acute
eukemia in 1970. Alex Fefer reported some success
ith identical twin BMT in the treatment of leukemia
69,70], but later studies revealed a higher rate of
elapse as compared with allogeneic BMT [71,72],
hus supporting the concept of an alloantigen-speciﬁc
VL effect. The publication in 1977 of Thomas and
olleagues’ [73] now-classic report on the results of
ransplantation of 100 patients with acute leukemia
arked the transition of BMT into a viable, if as yet
ess than perfect, form of therapy for leukemia and
elated diseases.
Controversies persisted about whether there was a
linical counterpart to the GVL effect that had been
escribed in animal models and whether there were
uman counterparts to murine tumor antigens. There
ere anecdotal reports of a GVL effect in humans
74], but Fefer et al. [70] stated that their data on 100
atients were inconclusive. By the end of the decade,
owever, Weiden and the team in Seattle [1] had
etrospectively analyzed 242 leukemia patients and
ound statistical evidence for an antileukemia effect
hat was associated with GVHD, although this did not
esult in any survival advantage. Subsequently, a lower
eukemia relapse rate and a signiﬁcant survival advan-
age were reported to be associated with the develop-
ent of chronic GVHD [75]. Clinically, the GVL
ffect was still associated with GVHD, and the ques-
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5ion of whether GVL and GVH were separable re-
ained unanswered.
ANIPULATION OF GVL AND GVH REACTIONS IN
NIMAL MODELS: THE QUEST CONTINUES
During the early 1980s, our team in Milwaukee
ocused attention on strategies to augment the GVL
ctivity of donor cells without exacerbating their
VH potential. Our approach was modeled in large
art after the work of Fefer and colleagues, who had
een successful at inducing leukemia-speciﬁc reactiv-
ty against MuLV-associated antigens in syngeneic
onors [41-43,76]. For 2 years we struggled with ways
o induce speciﬁc reactivity against spontaneous AKR
eukemia in donor cells without causing GVHD, to no
vail, and then there was a bit of serendipity. In what
as intended to be a “negative control” for immuni-
ation with allogeneic and xenogeneic leukemia cells,
e found that presensitization of H-2–matched donor
ice to alloantigens from third-party strains enhanced
he potency of the GVL effect against AKR leukemia
ithout altering GVH reactivity. In a report published
nNature, we showed that “alloimmunization” of CBA
H-2k) donor mice with cells from individual H-2–
ismatched third-party strains or pools of third-party
ells boosted GVL reactivity in vivo without exacer-
ation of GVH reactivity [77]. This contrasted with
mmunizations that used normal or leukemic AKR
ells, in which augmentation of GVL reactivity was
ccompanied by an increase in GVHD. I should em-
hasize that alloimmunization did not prevent the
ntrinsic GVH reactivity of the donor cells, but it did
mplify the GVL effect. Unimmunized H-2-matched
onor mice had no GVL reactivity, as measured in a
-day GVL bioassay, and had only mild to moderate
VH reactivity.
Eventually, we determined that the induction of
VL without exacerbation of GVH reactivity had
othing to do with the use of cells from MHC-mis-
atched donors [78,79] or even the so-called alien
istocompatibility antigens that were suspected in the
pre-genomic world” of that time [80,81]. GVL reac-
ivity could be augmented just as effectively by sensi-
ization to non–MHC-encoded antigens by using tis-
ues from H-2–matched mice. After alloimmunizing
he H-2k donor, we were able, for the ﬁrst time, to
btain a therapeutic GVL effect in AKR mice with
dvanced spontaneous acute T-cell leukemia by using
HC-matched instead of mismatched donors [79].
The discovery of T-cell growth factor [82-84]
rought on T-cell cloning [85,86] and new opportu-
ities for analyzing GVL and GVH effector cells. We
etermined that the GVL effector cells induced by
lloimmunization persisted long-term (56 days) in
he donor (ie, they were more like memory cells than v
10hort-lived activated killer cells) and that they were
yt-2 (CD8) T cells [87]. With the help of Mike
idmer and Fritz Bach, then at the University of
isconsin, we began to use limiting dilution analysis
LDA) assays to quantify the frequency of cytotoxic T
ymphocytes (CTLs) in the donor populations. We
ound that the difference between the strong and weak
VL reactivity of different donors was due to vari-
bility in the frequency of antigen-speciﬁc CTLs in-
uced by alloimmunization [87,88]. When the dose of
nfused cells was adjusted so that equivalent numbers
f CTLs were administered, GVL reactivity in vivo
as comparable. The frequency of alloreactive T cells
n naive MHC-matched mice was always very low:
ven when large numbers of naive cells were given, the
rowth of AKR leukemia outpaced the naive immune
esponse, resulting in an ineffective GVL reaction
87,88].
We used split-well LDA assays to compare lysis of
eukemic versus nonleukemic AKR cells by CTLs
rom allosensitized donors that had a high statistical
robability (P  .98 to .999) of being clonal in origin
87,88]. Some of these putative “clones” seemed to be
eukemia speciﬁc by exhibiting a statistically signiﬁ-
ant kill of leukemic, but not nonleukemic, AKR cells.
ew of the clones lysed nonleukemic AKR T cells
xclusively; more lysed both target sets. Using block-
ng assays, we subsequently established that the reac-
ivity of these CTLs, including most that initially
eemed to be leukemia speciﬁc, was directed against
iHA or nonclassic MHC class Ib antigens (such as
a-1) that were shared by both the AKR host and the
train that had been used to alloimmunize the H-2k
onor [88]. Thus, in actuality, the process of alloim-
unization selectively primed the donor against a
imited set of host alloantigens, ie, those shared by
KR and the alloimunizing strain, but not the donor
88-90]. In vivo priming against these shared alloan-
igens was sufﬁcient to augment reactivity against leu-
emia, but it did not exacerbate the GVH potential
xcept when the strain used to presensitize the donor
hared too many (or perhaps certain immunodomi-
ant) alloantigens with AKR.
Our failure to generate CTL clones that were
ruly leukemia speciﬁc in the AKR model perplexed
s, but as our understanding of the signals required to
ctivate T cells and the nature of trimolecular T-cell
eceptor/MHC/peptide interactions evolved, the basis
or such failure became clear. William Green, in par-
icular, has carefully dissected the elements that con-
rol immune reactions to MuLV-associated antigens,
uch as those present in spontaneously arising AKR
eukemia [91-103]. Some of the mechanisms that limit
eactivity to MuLV-associated antigens are listed in
able 1. Although most human leukemias do not have
retroviral etiology, these mechanisms may be rele-
ant to the failure of current efforts to induce leuke-
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Mortimer M. Bortin Lecture
Bia-associated antigens in the more recalcitrant ma-
ignancies, such as acute lymphoblastic leukemia.
hen confronted with such stealth, alloantigens may
e the most (or only) effective targets for immune-
ediated elimination of leukemia.
F GERM-FREE MICE AND SUPPRESSOR T CELLS
My own career in animal models of BMT and
eukemia began at the University of Notre Dame’s
obund Laboratory in 1972. Lobund was the birth-
lace of germ-free research in the United States, and
orris Pollard asked me to work on BMT in germ-
ree mice, following up on work started by Sister John
iriam Jones, Brother Raphael Wilson, and Pat
ealmear [112]. We used the AKR acute T-cell leu-
emia model, along with SJL mice that spontaneously
eveloped a Hodgkin-like reticulum cell sarcoma, in
ur studies [51,52,113,114]. After moving to Milwau-
ee to work with Bortin, I developed protocols for
endering mice bacteria free by using antibiotic de-
ontamination and a laminar airﬂow protective envi-
onment. There is evidence that the host microﬂora
nﬂuences the incidence and intensity of GVH disease
n both humans and animals [112,115-119]. Veenen-
all et al. [117] even proposed a form of “biotyping” to
atch donor and host microﬂora. Also, infection, the
rimary cause of death in mice undergoing BMT, did
ot occur in germ-free mice. Using the antibiotic
econtamination/laminar airﬂow protective environ-
ent, we were able to study the antileukemic effect of
VHD in MHC-mismatched BM chimeras that oth-
rwise would have succumbed to infection and died.
We had success in manipulating GVH reactivity
o obtain signiﬁcant leukemia-free survival in AKR
ice with advanced spontaneous leukemia by using a
ombination of chemoradiotherapy and MHC-mis-
atched (SJL, H-2s) BMT [120]. Donor LN cells
ere essential for elimination of the leukemia, but too
any LN cells resulted in increased GVHD and mor-
ality. Relapse was the major cause of death with either
llogeneic BM alone or with autologous BM with or
ithout LN cells.
We estimated the frequency of alloreactive CTLs
able 1. Mechanisms Thought to Contribute to a Failure to Generate
eukemia-Speciﬁc T Cells in AKR Mice
Central tolerance due to lifelong viremia [97,104,105]
Lack of MHC-restricting elements [92,94,96]
Lack of essential co-stimulatory molecules on T-cell leukemia
[106]
T-cell anergy [91,95,107,108]
T-cell ignorance of processed peptides [99,109-111]
Lack of peptide processing [109]
Regulatory control (ie, suppression) [95-98]n BM chimeras by using LDA assays in these studies p
B&MT120], looking for quantitative parameters that could
ccount for clinical outcome. In some allogeneic chi-
eras, we detected donor anti-host suppressor T cells,
s evidenced by a characteristic check-shaped LDA
urve. From one such chimera, our colleague Charles
hih isolated a donor T cell clone, called SAC-9.12,
hat was speciﬁc for host H-2Ek alloantigen [121-123].
his clone speciﬁcally suppressed generation of donor
nti-host CTLs in vitro. Furthermore, when injected
nto SJL3AKR (H-2s3H-2k) BM chimeras, SAC-
.12 cells completely suppressed host-speciﬁc CTLs
nd moderated GVH mortality in a dose-dependent
anner, but it had no effect on CTL generation and
VHD in third-party (SJL3DBA/2; H-2s3H-2d)
himeras [122,123].
We do not know precisely how the emergence of
hese regulatory/suppressor cells affected the fate of
ndividual BM chimeras. Evidence of suppression was
ound in chimeras as early as 14 days and as late as 166
ays after BMT [120]. Suppressor T cells may con-
ribute to the development of donor-host tolerance
nd thereby increase the survival rate, or they may
lunt allospeciﬁc GVL reactivity and increase the risk
f relapse. Regardless, these studies established the
lonal nature of T-cell suppression in BM chimeras
nd validated the potential for using suppressor T-cell
lones to prevent GVHD. Suppressor cells lost favor
uring the 1980s, in part because of the inability to
dentify a unique cell phenotype. Recently, suppressor
ells have been elevated to “professional” status and
ained new life as regulatory cells [124]. These cells
ave distinctive functional properties and phenotypes
eg, CD25, foxp3, GITR, CTLA-4, and CD62L).
hey are not lytic, but suppression requires cell-cell
ontact.
We did not detect lytic activity in the SAC-9.12
uppressor T-cell clone; however, when Shih tested T
ells recovered from an SJL3AKR BM chimera in-
used with SAC-9.12 cells, he isolated a donor-derived
3T4 (CD4) T-cell clone (called SATC) that spe-
iﬁcally lysed host H-2Ek target cells in vitro [125]. A
ovel characteristic of this clone was that its lytic
ctivity was manifested only in the absence of inter-
eukin-2. SATC cells could be repeatedly cycled be-
ween a lytic and a nonlytic phenotype by alternate
xposure to alloantigen and then interleukin-2. At the
ime, we did not have the tools to determine whether
he lytic SATC clone was derived from the infused
onlytic SAC-9.12 clone, but they shared the same
-cell phenotype and antigen speciﬁcity. Given the
emonstration by Shlomchik et al. [126] that induc-
ion of GVH is dependent on the presence of host
ntigen-presenting cells (APCs), one wonders
hether infusion of T cells that have the ability to
liminate host MHC class II APCs in vivo might
revent activation of CD8 CTLs and moderate
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5VHD, as we observed with the SAC-9.12 clone
122,123].
Another interesting ﬁnding from studies with bac-
eria-free BM chimeras was the high rate of leukemia
elapse in donor cells that accompanied improved
ong-term survival (unpublished data) [120]. This was
ttributed to susceptibility of the allogeneic SJL donor
o the dualtropic retrovirus that persisted in the host
fter transplantation. Iwai and colleagues [127], work-
ng in the laboratory of Robert Good, explored issues
elated to the resistance and susceptibility of marrow
onors to MuLV. Malignant transformation of donor
ells is relatively rare in humans, as noted by Kolb and
ender-Gotze [128] in an early review on late com-
lications of BMT, but it has been reported [129-133].
etroviral transformation is only one, and probably
ot the most likely, of several mechanisms to explain
he phenomenon in humans.
Subsequently, we identiﬁed a variety of factors
hat inﬂuenced the delicate balance between induction
f GVHD and induction of donor-host tolerance
134,135]. Principal among these were the dose and
ype of T cells, as well as the intensity of the condi-
ioning regimen. At an International Workshop on
ellular Immune Mechanisms and Tumor Dormancy
rganized by Tom Stewart and Fred Wheelock in
ttawa in 1991, we presented experimental data on 4
actors that contribute to late leukemia relapse after
MT: (1) mixed T-cell chimerism, (2) development of
onor-host tolerance, (3) susceptibility of the leuke-
ia to GVL/GVH effector cells, and (4) suboptimal
VL/GVH reactivity [136]. We reported that estab-
ished MHC-matched B10.BR3AKR chimeras that
ad resisted an early challenge with AKR leukemia
uccumbed to a later challenge with the same leuke-
ia, suggesting the absence of memory and loss of
VL reactivity over time [136]. This was not unique
o our model system. Colleagues have related to me
necdotal stories of similar ﬁndings in other models.
urthermore, Megan Sykes and colleagues [137] re-
ently reported that host APCs are necessary for the
VL effect associated with donor leukocyte infusion
DLI). They observed a loss of DLI-mediated GVL
ffects in mixed chimeras established with a reduced-
ntensity conditioning regimen [138]. Extinction of
he GVL effect correlated with conversion of the host
o full donor chimerism.
The delicate balance between GVH and tolerance
as dramatically illustrated in our studies with F(ab)2
ragments of anti-CD3 monoclonal antibodies to in-
uce tolerance in B10.BR3AKR chimeras [139,140].
e found that the T cell–speciﬁc monoclonal anti-
ody could be used successfully in vivo to avoid severe
VHD but that excessive or ill-timed administration
f monoclonal antibody eliminated GVL reactivity,
eading to leukemia relapse. Of note in these experi-
ents, even when leukemia was eliminated from the c
12ymphoid tissues in some mice (as conﬁrmed by poly-
erase chain reaction analysis), relapse occurred in
xtralymphoid sites (eg, in the liver and along the
pinal column). These slow-growing relapse lympho-
as sometimes contained inﬁltrating CD4 and
D8 donor T cells. Upon transfer to naive AKR
osts, the lymphoma cells caused fulminate and fatal
isease (R. Truitt, unpublished data). These studies
uggest that whether tolerance evolves naturally or is
ntentionally induced, sequestered or persistent tumor
ells are a potential problem. Immune reactivity
gainst nonhematologic malignancies may be even
ore problematic in this regard. Tumor- or alloanti-
en-speciﬁc GVT effector cells may need to persist in
ivo and also get into tissues that harbor residual
isease.
NTO THE FRAY: NEW INVESTIGATORS AND NEW
FFECTORS
Throughout the 1980s, the struggle to separate
VL and GVH reactivity was joined by a whole new
adre of investigators who brought new models and
ver-newer approaches to the problem. Insights into
he pathophysiology of the GVH syndrome (ne´e sec-
ndary disease) and its cellular and noncellular mecha-
isms provided new fodder for efforts to separate
VL and GVH [141-148]. The role of T-cell subsets,
atural killer (NK) cells, and cytokines in GVH and
VL reactivity was demonstrated (Figure 1B). New
ethods for manipulating T cells emerged. By the end
f the decade, it was clear from work in animal models
hat distinct and overlapping effector cell populations
ediated GVL and GVH reactions.
We, along with many others, pursued GVL/GVH
tudies with antigen-speciﬁc T cells, as well as lym-
hokine-activated killer (LAK) and other GVL effec-
or cells, in the 1980s [88,149-152]. These studies
ave been reviewed elsewhere, and I will not cover
hem here. However, I would like to make note of the
roceedings of an International Symposium on Cel-
ular Immunotherapy of Cancer because it was co-
rganized by Bortin, along with Robert Gale and
yself [153]. Among the highlights of this meeting,
eld in the fall of 1986, were “advances in technolog-
cal methods to identify, isolate, activate, and expand
ells of the immune system having highly speciﬁc as
ell as broad lytic activity against cancer cells” [153;
reface]. Work by Grimm, Herberman, Rosenberg,
ondel, Mule´, and many others in characterizing LAK
ells, NK cells, tumor-inﬁltrating lymphocyte cells,
nd other effector populations was presented, as was
ork on regulation and trafﬁcking of cells adminis-
ered for adoptive immunotherapy, including the po-
ential for GVL reactivity. Almost 20 years later, many
olleagues still recall with fondness the excitement of
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Bhat conference held in the unique ambiance of Frank
loyd Wright’s Wingspread near Racine, WI.
By this time, Bortin and I had independently
oved to the Medical College of Wisconsin. He
oined the Department of Medicine in 1983, devoting
is attention to the IBMTR. I moved my laboratory
roup into the Department of Pediatrics the following
ear, where Ann LeFever, Charles Shih, and I contin-
ed to work on clonal analysis of GVL and GVH
ffector cells. In these studies [87,88,154-158], we
ere able to establish or verify a number of principles,
uch as (1) a single miHA-speciﬁc T-cell clone could
ause lethal GVHD, but not all miHA-speciﬁc CTL
lones did so; (2) lytic activity in vitro did not predict
VH reactivity in vivo; (3) cloned CTLs persisted in
ivo and did not need exogenous interleukin-2 to
unction; (4) the length of time in culture adversely
ffected the homing characteristics of ex vivo–ex-
anded CTLs and, as a consequence, their GVL efﬁ-
acy in vivo; and (5) T cells are not the only GVL
ffector cells. We also identiﬁed nonclassic MHC
lass Ib (Qa-1b) alloantigen as a target antigen for
VL reactivity without GVHD in AKR mice
88,155,157]. It is still not clear to me, however,
hether tissue-restricted expression of the Qa-1 tar-
et antigen was responsible for the lack of GVHD or
hether the intrinsic functional properties of the
TLs (perhaps their cytokine proﬁle) determined
hether such clones caused GVHD. LeFever adapted
nzyme kinetics analysis techniques to the study of
loned CTLs, viewing the effector CTL as an “en-
yme” with the target cells as its “substrate” [156,157].
his allowed us to quantitatively compare different
TL clones with different target cells (eg, leukemic
ersus nonleukemic) on the basis of their lytic efﬁ-
iency and intrinsic afﬁnity.
EEKING SEPARATION OF GVL AND GVH IN THE
LINIC
During the 1980s, clinical BMT beneﬁted from
apid improvements in the care and management of
atients, as well as a broader acceptance of its use in
he treatment of hematologic malignancies [159,160].
here were intense efforts to manipulate the immune
epertoire in patients. T-cell depletion (TCD) became
e rigueur, and a panoply of approaches were tried
161-169]. Some groups attempted complete TCD
nd concluded that it would not work. Others tried
artial or T-cell subset depletion, with variable levels
f success. At the Medical College of Wisconsin, we
orked with Robert Ash to quantify the level of TCD
n donor marrow with 2 different monoclonal anti-
odies (T10B9 and T12A10, produced by John
hompson at the University of Kentucky) by using
DA assays. We found that excessive depletion (2 p
B&MTog10) was linked to increased graft failure and relapse
162,166]. Other groups had similar experiences. Al-
erto Marmont and colleagues [169] summarized the
tate of TCD in a review in 1991. The primary lessons
earned from these many studies were that T cells help
o ensure donor engraftment and contribute to a ben-
ﬁcial antileukemia effect in some patients [170]. By
he end of the 1980s, attempts were being made in the
linic to intentionally manipulate GVHD to take ad-
antage of the GVL effect, including early stoppage of
osttransplantation immunosuppression [171] and in-
uction of autologous GVHD by altering thymic se-
ection [172,173]. Unfortunately, as in animal models,
he presence of GVHD did not always guarantee a
VL effect and a survival beneﬁt. The concept of
yngeneic (or autologous) GVHD was not entirely
ew. Sljivic [174] had described syngeneic secondary
isease in mice in 1966, and Barnes and Loutit [175]
ad described acute GVHD in identical twins in 1979.
owever, it was primarily through the work of Alan
ess and his colleagues [reviewed in 176] that synge-
eic/autologous GVHD developed into a practical
herapeutic tool.
In 1990, Mary Horowitz and colleagues [71] ana-
yzed data from the IBMTR on 2254 patients with
early” leukemia (acute lymphoblastic leukemia in ﬁrst
omplete remission, acute myelogenous leukemia in
rst complete remission, and chronic myelogenous
eukemia in chronic phase) who received HLA-
atched sibling BM transplants. In this oft-cited ar-
icle, 3 types of GVL reactions in recipients of HLA-
atched sibling grafts were described: (1) an
ntileukemic effect associated with GVHD, (2) an
ntileukemic effect independent of clinically evident
VHD, and (3) an antileukemic effect that was inde-
endent of GVHD but was altered by TCD of the
onor BM. The biological basis for these effects was
ot clear, and there was variability between different
ypes of leukemia. However, around this time, inves-
igators such as Goulmy and Falkenberg in The Neth-
rlands began to report the isolation of (1) alloanti-
en-speciﬁc, (2) leukemia-speciﬁc, and (3) dual-
peciﬁc (alloantigen and leukemia) T-cell clones from
ransplant patients [177-184]. This provided a partial
xplanation for the clinical data and also substantiated
he clonal nature of GVL and GVH reactions sug-
ested by our animal studies a decade earlier. The
bility to distinguish between GVL- and GVH-reac-
ive T cells has now evolved to the level of molecular
haracterization of the T-cell receptor, with different
-cell populations having leukemia reactivity, allo-
eactivity, or dual reactivity [185-187]. Animal models
re being used to conﬁrm the GVL and GVH reac-
ivity of T-cell subpopulations identiﬁed and isolated
n the basis of their distinct V T-cell receptor ex-
ression [188].
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5OU CAN HAVE ONE WITHOUT THE OTHER!
As noted previously, our understanding of the bi-
logical basis for both GVH and GVL reactivity ad-
anced signiﬁcantly in the years leading up to the
990s. The clonal basis for both GVL and GVH
eactivity now was ﬁrmly established (Figure 1C). The
elative contributions of CD4 and CD8 subsets to
VL/GVH reactivity were being worked out. Ad-
ances in other areas of immunology pointed the way
o an understanding of the differences in GVH po-
ential of allospeciﬁc T cells. The potent GVH-in-
ucting capacity of some CD8 CTL clones, which
e had observed earlier, was most likely due to their
ecretion of type 1 cytokines. Other lytic CD8 clones
id not secrete such proinﬂammatory cytokines, thus
ccounting for the lack of correlation between lytic
ctivity and GVHD. Dan Fowler and Ron Gress [189-
91] have been at the forefront of showing that GVL
nd GVH reactivity can be manipulated on the basis
f the cytokine proﬁles of the CD4 and CD8 pop-
lations, and they continue to translate these to the
linic [192]. A distinct contribution of different lytic
athways (ie, Fas/FasL and perforin/granzyme) to
VL and GVH reactivity also has been reported
193-197], as has the GVL effector role of CD4 T
ells [182,193,198].
NK and LAK cells emerged as potential GVL
ffector cells in the late 1980s and throughout the
990s [88,149,152,173,199-202]. Several groups laid
he groundwork for immunotherapy with NK cells in
he context of BMT (see review [203]), building on the
eminal observations on hybrid resistance by Cudkow-
cz and Bennett [204,205]. Subsequent identiﬁcation
f the inhibiting and activating molecules on NK cells
eg, killer cell immunoglobulin-like receptors [KIRs]
n humans; Ly49 and CD94/NKG2 receptors in mice;
ee review [206]) has allowed for the design of rational
trategies to exploit their activity. Ruggeri, Velardi,
artelli, and their colleagues have exploited the GVL
otential of alloreactive NK cells in humans [207-
10]. Similar successes are being achieved with cyto-
ine-induced NK T cells [211-215].
Of all the recent developments in the use of BMT
or treatment of leukemia and related malignancies,
erhaps none has had as much effect as DLI therapy.
lthough others had used infusions of donor lympho-
ytes previously, it was the success reported by Kolb
nd colleagues [216,217] in Germany treating post-
ransplantation relapse that spurred the ﬁeld in a new
irection. Now DLI offers a practical way to provide
ellular immune therapy in the setting of blood or
arrow transplantation with a lower risk of GVHD.
here have been some excellent reviews of DLI ther-
py in the clinical setting [218-222], so I will not cover
hat here; however, I would like to describe work in an
nimal model developed by Bryon Johnson in our
14aboratory, because it led to a recognition of the role
hat regulatory T cells played in diminished GVHD
fter DLI therapy.
Johnson, who joined our team as a postdoctoral
ellow in 1989, developed a model [223-225] to sim-
late the clinical DLI studies performed in our BMT
rogram by Drobyski et al. [226]. The mechanisms by
hich delayed infusion of T cells resulted in less
evere GVHD were not clear at the time. Among the
ossibilities under consideration were temporal sepa-
ation of the T cells from the proinﬂammatory cyto-
ines induced by the conditioning regimen and turn-
ver of APCs from host to donor. Johnson found that
LI led to full conversion of the host to donor chi-
erism without GVHD, broke the donor-host toler-
nce that developed when BM alone was given, and
llowed for the persistence of an effective GVL reac-
ion [223-225]. He quantiﬁed the potency of the GVL
ffect of DLI therapy with CD4 and CD8 T-cell
ubsets [225] and used LDA assays to show that allo-
eactive CD4 T cells were preferentially inhibited
ver CD8 CTLs [224]. The fact that 2 to 3 weeks
ere required before BM-transplanted mice had full
rotection against DLI-mediated GVHD caught our
ttention. That time frame matched the time required
or reconstitution of the host thymus; therefore, we
xamined the effect that pretransplantation thymec-
omy or depletion of newly synthesized donor-BM-
erived T cells had on DLI-associated GVHD. We
bserved severe and fatal GVHD in both cases [227].
sing various knockout donors, we established that
D4 CD25 regulatory T cells (Treg) arising de
ovo from donor BM in the repopulating host thymus
ere primarily responsible for protection from
VHD [228,229]. Furthermore, adoptive transfer of
D4 CD25 Treg cells restored protection from
VHD after DLI therapy in hosts that lacked endog-
nous Treg cells (B.D. Johnson, unpublished data).
The potential for using adoptively transferred reg-
latory T cells to protect from GVHD has now been
rmly established by several laboratories [230-234],
nd a number of investigators have shown that this can
e done without loss of the GVL effect [235-242].
D4 CD25 Treg cells are not the only cells that
an inﬂuence GVH reactivity, as illustrated by the
ork of Sato et al. [237] and Billiau et al. [239]. We are
racking the emergence of CD4 CD25 Treg cells
n our BMT patients [243]. We speculated that failure
f the thymus to produce Treg cells might contribute
o the risk of GVHD, especially chronic GVHD,
here suppression of autoreactive T cells may be
mportant. Nonmyeloablative conditioning or other
hymus-sparing measures may protect from DLI-as-
ociated GVHD. However, recent clinical data sug-
est that CD4 CD25 Treg cells are increased in
atients with chronic GVHD [244].
As noted previously, the persistence of the GVL
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Bffector mechanism in the setting of DLI may be a
roblem. Like Marpara et al. [138], Johnson found
hat a long-term memory response to AKR leukemia
rechallenge at 100 days after DLI) failed to develop
n his DLI model unless the mice were co-infused
ith host (AKR) dendritic cells (Guliang Xia, unpub-
ished data). Furthermore, even at this late time,
D4 CD25 Treg cells were responsible for the
uppression of GVHD (B.D. Johnson, personal com-
unication).
Cytokines have emerged as a treatment option for
eparating the GVL effect from GVHD. Cytokines
ffer a means to prevent GVHD or possibly protect
ost tissues from GVH reactivity while allowing GVL
ffector cells to function at an adequate level. The
aboratories of Megan Sykes [245-250] and James
.M. Ferrara [251-256] in particular have actively
ursued this line of investigation. Other investigators
re trying alternative strategies that may ultimately
ead to molecular targeting of (1) the host APCs that
rigger GVHD, (2) the actual GVH effector cells, (3)
he tissues most vulnerable to attack, or (4) a combi-
ation of these. Among the exciting and novel ap-
roaches are co-stimulatory blockade, stimulation of
egative immune signals, molecular targeting of dif-
erent signaling pathways, modulating the trafﬁcking
f effector cells, and blockade of pathogenic molecules
r cells [257-279].
With advancements in our understanding of leu-
emia- and other tumor-associated antigens (whether
xogenous, endogenous, or mutated or not) [280] and
ngoing development of procedures to induce, isolate,
xpand, and even genetically engineer antigen-speciﬁc
-cell clones [281-286], the ﬁeld of BMT is poised to
ake an unprecedented leap toward reshaping GVL
eactivity into the GVT reactivity envisioned earlier.
ow, as before, GVL/GVH animal models will play
n important role in answering questions and resolv-
ng issues about effective clinical use of DLI therapy.
ur biggest obstacle clinically may now be regulatory
ssues and agencies and not immunobiology.
HAT OF THE FUTURE?
A detailed accounting of scientiﬁc achievements
uring the last decade of GVL/GVH research would
equire more space than has been allotted to me here,
nd recent reviews are available. I would be remiss,
owever, if I did not comment on the future. So, with
ue diligence, I present a list of areas that I see as
aving potential to signiﬁcantly affect the ﬁeld of
VL/GVH research (Table 2). What is clear from
his list is that the arsenal of weapons available and
pproaches for separating GVL and GVH continues
o grow, as does our knowledge of immunology and of
ur enemy—cancer. Clinical studies designed to take
B&MTdvantage of the antitumor effect of allogeneic BMT
nd DLI therapy seem to be moving the ﬁeld faster
ow than animal studies—this is quite different from
he early days. However, animal models will always be
mportant tools for testing new concepts and new
pproaches. Humanized SCID-NOD mice now and
nimal models emerging in the future will allow us to
tudy and manipulate human cells in vivo. Innovations
n imaging technology already allow us to visualize the
attles between responder cells and APCs or between
ffector cells and their targets or even to monitor the
ffects of regulatory cells on GVL/GVH effector cells
n real time. In the new postgenomic world, we have
nly begun to scratch the surface of the awesome
otential for molecular interventions that eventually
ay allow us to block GVH reactions and target GVT
esponses at will and, it is hoped, for any malignancy.
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